PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA 2)
3 janvier 2008 mis à jour par: Anthera Pharmaceuticals
Phospholipase Levels And Serological Markers of Atherosclerosis 2: An Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease
The study will be conducted at up to 25 U.S. centers and will be a double-blind randomized parallel group placebo controlled study among subjects with stable coronary artery disease (CAD).
Subjects will be randomized to receive either placebo tablets or one of 2 orally active doses of A-002.
The duration of study drug therapy will be 8 weeks.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
A-002 represents a novel therapy for the treatment of atherosclerosis and coronary artery disease (CAD).
Through the inhibition of activity A-002 may provide multifunctional activity directed against key facets of the disease process, namely a) inflammation, b) atherogenic lipid profiles and c) the atherosclerotic process.
Non-clinical and clinical data from recent studies have demonstrated the benefit of early and aggressive anti-inflammatory therapy to reduce cardiovascular risk.
Recent clinical studies have provided a strong association between levels and cardiovascular event risk.
The proposed Phase 2 clinical pharmacology study (Study No. AN-CVD-2222) will examine the effects of 2 different doses of A-002 compared with placebo, on enzyme levels and activity after 8 weeks of treatment.
In addition, the effect of treatment on inflammatory markers of cardiovascular risk (C-reactive protein [CRP]), lipid levels and lipoprotein subclasses and other soluble biomarkers (e.g., ICAM-1, VCAM-1, TNF, MCP-1 etc) will also be assessed.
Type d'étude
Interventionnel
Inscription (Anticipé)
120
Phase
- Phase 2
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Alabama
-
Mobile, Alabama, États-Unis, 36608
- Mobile Heart Specialists
-
-
Arizona
-
Scottsdale, Arizona, États-Unis, 85260
- Sonoran Health Specialists
-
-
Florida
-
Hudson, Florida, États-Unis, 34667
- Pasco Cardiology Center
-
Port Charlotte, Florida, États-Unis, 33952
- Charlotte Cardiovascular Institute
-
Tampa, Florida, États-Unis, 33609
- Florida Cardiovascular Research Institute
-
-
Georgia
-
Augusta, Georgia, États-Unis, 30901
- Augusta Cardiology Clinic
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40207
- Louisville Cardiology Medical Group
-
-
Maine
-
Auburn, Maine, États-Unis, 04210
- Maine Research Associates
-
-
New York
-
Binghamton, New York, États-Unis, 13901
- United Medical Associates
-
Syracuse, New York, États-Unis, 13210
- Cardiology PC
-
-
Texas
-
Austin, Texas, États-Unis, 78705
- Austin Heart
-
-
Virginia
-
Norfolk, Virginia, États-Unis, 23507
- Clinical Research Associates of Tidewater
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis, 53715
- Wisconsin Heart, SC
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
Subjects are eligible for inclusion if they meet the following inclusion criteria:
- Men and women ≥18 years of age
- Written informed consent from the subject
- Stable CAD
- Stable medical condition, will be compliant and able to comply with the requirements of the protocol
Exclusion Criteria:
Subjects must NOT meet any of the following exclusion criteria:
- Planned coronary artery bypass surgery (CABG)
- Acute or chronic heart failure as defined by the New York Heart Association (NYHA) classification as functional Class III or Class IV
- Hospitalization for acute coronary syndrome (ACS) if troponin >0.1 ng/mL in the preceding 6 weeks
- Hospitalization for ST-segment elevation acute myocardial infarction (STEMI) in the preceding 12 weeks
- Subjects with chronic inflammatory disease (e.g., rheumatoid arthritis), inflammatory bowel disease, recent (12 weeks) systemic or localized infection (the latter requiring clinical intervention), or major surgery
- hs-CRP ≥15 mg/L repeated on at least 2 occasions >24 hours apart due to non-cardiovascular systemic inflammatory conditions (e.g., rheumatoid disease)
- Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening or prior experience with A-002.
- Subjects treated for cancer within the previous 5 years except for skin basal cell carcinoma or carcinoma in situ of the cervix, with measures other than a minor, complete surgical excision (e.g., chemotherapy), or radiation therapy
- Subjects who have received immunosuppressant therapy within 30 days prior to entry
- Subjects who have received anti-tumor necrosis factor (for example, infliximab) therapy within 6 months prior to entry
- The presence of severe liver disease with cirrhosis, recent active hepatitis, active chronic hepatitis, ALT or AST >3 x upper limit of normal, biliary obstruction with hyperbilirubinemia (total bilirubin >2 x upper limit of normal)
- Active cholecystitis, gall bladder symptoms, or potential hepato-biliary abnormalities
- The presence of moderate or severe renal impairment (CrCl <60 mL/min or creatinine >1.5 x upper limit of normal), nephrotic syndrome, or subjects undergoing dialysis
- Uncontrolled diabetes mellitus (known HbA1c >11% within the last 1 month prior to screening)
- Females who are nursing, pregnant, or intend to become pregnant during the time of the study, or subjects who have a positive serum pregnancy test at Visit 1 (if the subject is a female of child-bearing potential). Women of child-bearing potential must also use a reliable method of birth control during the study and for 1 month following completion of therapy. A reliable method for this study is defined as one of the following: oral or injectable contraceptives, intrauterine device (IUD), contraceptive implants, tubal ligation, hysterectomy, a double-barrier method (diaphragm with spermicidal foam or jelly, or a condom).
- Subjects who have a history of alcohol or drug abuse within 1 year of study entry
- Subject living too far from participating center or unable to return for follow-up visits
- Subjects who in the opinion of the Investigator are a poor medical or psychiatric risk for therapy with an investigational drug, are unreliable, or have an incomplete understanding of the study which may affect their ability to take drugs as prescribed or comply with instructions
- Known human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C Virus (HCV) infection
- Treatment with any systemic corticosteroid within the 30-day period prior to study entry or the use of inhaled steroids within the 14-day period prior to study entry
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
|---|
|
The primary objective of this study is to determine the effect of once daily (QD) dosing of A-002 on sPLA2 levels and activity
|
Mesures de résultats secondaires
Mesure des résultats |
|---|
|
Determine the effect of QD dosing of A-002 on sPLA2 levels and activity at each time point (Weeks 2, 4, and 8)
|
|
Compare the effect of QD dosing of A-002 on sPLA2 enzyme levels and markers of inflammation
|
|
Determine plasma drug concentrations with QD dosing
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 septembre 2007
Achèvement de l'étude
1 décembre 2007
Dates d'inscription aux études
Première soumission
4 septembre 2007
Première soumission répondant aux critères de contrôle qualité
5 septembre 2007
Première publication (Estimation)
6 septembre 2007
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
7 janvier 2008
Dernière mise à jour soumise répondant aux critères de contrôle qualité
3 janvier 2008
Dernière vérification
1 janvier 2008
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- AN-CVD2222
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .